Evidence map›Paper›PMID 31128065›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2019

TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population

Ameen Abdulaziz Mohammed Basabaeen, Enaam Abdalrhman Abdelgader, Ebtihal Ahmed Babekir, Saadia Osman Abdelrahim, Nada Hassan Eltayeb, Osama Ali Altayeb, Eman Abbass Fadul, Abdulwali Sabo, Ibrahim Khider Ibrahim

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Frontiers in oncology · 2023
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Ameen Abdulaziz Mohammed BasabaeenDepartment of Haematology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan.
Enaam Abdalrhman AbdelgaderDepartment of Pathology, Faculty of Medicine, Al Neelain University, Khartoum, Sudan.
Ebtihal Ahmed BabekirDepartment of Haematology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan.
Saadia Osman AbdelrahimDepartment of Haematology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan.
Nada Hassan EltayebDepartment of Physiology, Faculty of Medicine, Al Neelain University, Khartoum, Sudan.
Osama Ali AltayebFlow Cytometry Laboratory for Leukemia &Lymphoma Diagnosis, Khartoum, Sudan.
Eman Abbass FadulFlow Cytometry Laboratory for Leukemia &Lymphoma Diagnosis, Khartoum, Sudan.
Abdulwali SaboDepartment of Statistics, School of Medical Sciences, University Sains Malaysia, Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia.
Ibrahim Khider IbrahimDepartment of Haematology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan.
Al-Neelain University · SDHadhramout University · YEUniversiti Sains Malaysia · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed at exploring the association of TP53 72Arg/Pro polymorphism and Risk of Chronic Lymphocytic Leukemia and to assess the correlation between TP53 72Arg/Pro polymorphism and clinical parameter, hematological profile and some biological prognostic markers among Sudanese patients with chronic lymphocytic leukemia. Methods: A case-control study was conducted in Khartoum state, Sudan, during the period from April 2017 to April 2018, involved 110 B-CLL patients and 80 healthy volunteers as a control group. Physical examination, Complete Blood Count and Immunophenotype were performed in all patients to confirm the diagnosis. Clinical staging such as Rai and Binet were studied. CD38 and ZAP70 were performed by Flow Cytometry. Blood samples were collected from all participants; DNA was extracted by using ANALYTIKJENA Blood DNA Extraction Kit (Germany) and analyzed TP53 codon 72Arg/Pro Polymorphism by using AS-PCR. The statistical analysis was performed using SPSS version 23.0 software (Chicago, IL, USA). Results: the Arg/Pro was the most frequent genotype in B-CLL patients(50%), followed by Arg/Arg (25.5%) and Pro/Pro (24.5%), whereas in healthy control group Arg/Pro was the most frequent (47.5%), followed by Arg/Arg (45%) and Pro/Pro (7.5%). Our data indicate a higher frequency of homozygous Pro/ Pro in the B-CLL patients as compared to controls with an OR of 4.01 for the Pro/Pro genotype and lower frequency of Arg/Arg genotype in CLL patients as compared to controls with an OR of .42 for the Arg/Arg genotype. Also, the Pro allele showed higher risk than Arg allele (P value=0.000, OR 2.23, 95% CI=1.45-3.41). No significant association between gender, clinical staging systems (Rai, Binet), biological prognostic markers (CD38 expression or ZAP70 expression), and TP53 codon 72Arg/Pro polymorphisms, except Arg/Arg genotype tended to be associated with younger age (P =0.04). Conclusion: Our data suggested that Pro/Pro genotype contribute to increased susceptibility to B-Chronic Lymphocytic Leukemia risk in our population tenfold higher than those had Arg/Arg genotype.

Indexed as

AdultAgedAged, 80 and overAllelesCase-Control StudiesCodonDipeptidesFemaleGenetic Predisposition to DiseaseGenotypeHomozygoteHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedPolymorphism, Single NucleotidearginylargininearginylprolineCodonDipeptidesprolyl-prolineTP53 protein, humanTumor Suppressor Protein p5372 Arg/Pro PolymorphismCLLRiskSNPSudanTP53 gene

Identifiers

PMID31128065
PMCPMC6857868
OpenAlexW2946211132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.